{"gene":"ADORA2B","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2012,"finding":"Adora2b signaling during myocardial ischemia leads to stabilization of the circadian rhythm protein Per2, which in turn stabilizes HIF-1α, enabling a HIF-dependent metabolic switch to oxygen-efficient glycolysis that is cardioprotective; Per2-/- mice lack this metabolic shift and have larger infarct sizes.","method":"Genetic knockout mice (Adora2b-/-, Per2-/-), metabolic studies, ischemic preconditioning model, light-induced Per2 stabilization with transcriptional induction of glycolytic enzymes","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal genetic models and functional metabolic readouts, replicated across multiple experimental conditions","pmids":["22504483"],"is_preprint":false},{"year":2012,"finding":"Adora2b signaling on bone marrow-derived cells, specifically polymorphonuclear neutrophils (PMNs), dampens myocardial ischemia-reperfusion injury by suppressing TNF-α release from PMNs.","method":"Bone marrow transplantation between WT and Adora2b-/- mice, neutrophil depletion, Adora2b agonist treatment, cytokine profiling, pharmacologic studies on human activated PMNs","journal":"Anesthesiology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal bone marrow transplant experiments plus neutrophil depletion and pharmacologic validation in human cells","pmids":["22531331"],"is_preprint":false},{"year":2012,"finding":"Adora2b signaling on T cells enhances regulatory T cell (Treg) differentiation; Adora2b-/- T cells fail to differentiate into Tregs upon adenosine receptor activation, and Adora2b-deficient mice exhibit more severe endotoxin-induced pulmonary inflammation with impaired Treg induction.","method":"Pharmacologic Adora2b activation, Adora2b-/- mice, endotoxin-induced pulmonary inflammation model, flow cytometry for T cell subsets","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — clean genetic KO with defined cellular phenotype, single lab","pmids":["22389701"],"is_preprint":false},{"year":2012,"finding":"Adora2b signaling on neutrophils constrains TNF-α production during renal ischemia-reperfusion; reconstitution of Adora2b-/- mice with TNF-α-deficient neutrophils rescued the injury phenotype, placing Adora2b upstream of neutrophil-dependent TNF-α in acute kidney injury.","method":"Adora2b-/- mice, TNF-α antibody blockade, Tnf-α-/- mice, neutrophil depletion and reconstitution, renal ischemia-reperfusion model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis via adoptive transfer/reconstitution plus multiple loss-of-function models with defined phenotype","pmids":["23028059"],"is_preprint":false},{"year":2013,"finding":"Alveolar epithelial Adora2b signaling mediates ENT2-dependent lung protection during acute lung injury; dipyridamole-dependent attenuation of lung inflammation was abolished in mice with alveolar epithelial Adora2b deletion, establishing a crosstalk pathway between ENT2 and Adora2b.","method":"Ent1-/-, Ent2-/- gene-targeted mice, tissue-specific Adora2b deletion in alveolar epithelium, dipyridamole treatment, mechanical ventilation-induced ALI model","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific conditional KO plus pharmacologic rescue with defined pulmonary phenotype","pmids":["23603835"],"is_preprint":false},{"year":2013,"finding":"ADORA2B signaling in breast cancer cells downstream of Fra-1 transcription factor promotes filopodia formation and invasive activity; RNAi silencing or pharmacologic blockade of ADORA2B inhibited filopodia formation, invasion in vitro, and tumor outgrowth in lungs in vivo.","method":"Stable RNAi depletion, pharmacologic ADORA2B antagonism, in vivo xenograft metastasis assays, synthetic lethal drug screen","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple in vivo and in vitro orthogonal methods; Fra-1→ADORA2B axis established by RNAi and pharmacology","pmids":["23483055"],"is_preprint":false},{"year":2013,"finding":"ADORA2B signaling on vascular endothelium mediates protection from diabetic nephropathy; tissue-specific deletion of Adora2b in vascular endothelia (but not tubular epithelia) worsened nephropathy, and selective Adora2b agonist treatment was protective.","method":"Tissue-specific conditional knockout mice (endothelial vs. tubular), streptozotocin diabetic model, transgenic Adora2b reporter mice, selective agonist (BAY 60-6583) treatment","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific conditional KO with pharmacologic validation, multiple orthogonal approaches","pmids":["24262796"],"is_preprint":false},{"year":2013,"finding":"ADORA2B acts as a mechanoreceptor in enterochromaffin (EC) cells; under hypoxia, ADORA2B activates HIF-1α signaling via MAPK/CREB pathways and phosphorylates TPH-1 and activates VMAT-1 to stimulate serotonin (5-HT) synthesis and secretion.","method":"Hypoxia experiments on EC cells and IBD mucosa, antisense knockdown, NECA agonist, MRS1754 antagonist, Renilla luciferase under HRE control, PCR/western blot","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in cell model, antisense mechanistic confirmation, single lab","pmids":["23638125"],"is_preprint":false},{"year":2014,"finding":"ADORA2B signaling on myeloid cells (alternatively activated macrophages) drives lung fibrosis and pulmonary hypertension; conditional deletion of ADORA2B on myeloid cells attenuated fibrosis and PH with reduced IL-6, hyaluronan, CD206, and arginase-1.","method":"Conditional knockout mice (Adora2Bf/f-LysMCre), bleomycin-induced lung injury model, bronchoalveolar lavage, histology, lung function measurements","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific conditional KO with multiple molecular and physiological readouts","pmids":["25318478"],"is_preprint":false},{"year":2015,"finding":"ADORA2B mediates different cardioprotective mechanisms in a tissue-specific manner: endothelial and myocyte Adora2b mediates ischemic preconditioning, while inflammatory cell (PMN) Adora2b is required for protection from ischemia-reperfusion injury; adoptive transfer of Adora2b-/- PMNs confirmed the PMN-specific role.","method":"Tissue-specific conditional knockout mice (Lyz2-Cre, VE-cadherin-Cre, myosin-Cre crossed to floxed Adora2b), myocardial I/R and IP models, cytokine profiling, adoptive PMN transfer","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — three independent tissue-specific conditional KO lines plus adoptive transfer, multiple orthogonal readouts","pmids":["26136425"],"is_preprint":false},{"year":1995,"finding":"The human ADORA2B gene is located on chromosome 17p12; its pseudogene maps to chromosome 1q32. Partial sequence revealed an intron interrupting the coding region at the second intracellular loop, similar to A1 and A2a adenosine receptor genes.","method":"Fluorescence in situ hybridization (FISH), genomic cloning, partial sequence analysis","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 — direct structural/genomic characterization by FISH and sequencing, foundational paper","pmids":["7558011"],"is_preprint":false},{"year":2016,"finding":"Sevoflurane's hepatoprotective effects during liver ischemia-reperfusion require Adora2b signaling; sevoflurane inhibited platelet-neutrophil complex formation and reduced liver damage in wild-type but not Adora2b-/- mice, and increased Adora2b transcription and expression in liver tissue.","method":"Adora2b-/- and Adora2a-/- mice, liver IR model, flow cytometry, immunohistochemistry, real-time PCR, ex vivo human blood experiments","journal":"Anesthesiology","confidence":"Medium","confidence_rationale":"Tier 2 — global KO with functional phenotype and molecular readout, single lab","pmids":["27404219"],"is_preprint":false},{"year":2016,"finding":"Sustained activation of adenosine A2B receptors on myeloid cells promotes chronic pain by inducing nociceptor hyperexcitability via soluble IL-6 receptor trans-signaling; this mechanism was demonstrated in ADA-deficient mice, sickle cell disease mice, and CFA inflammatory pain models.","method":"Ada-/- mice, sickle cell disease mouse model, CFA inflammatory pain model, myeloid-specific ADORA2B manipulation, behavioral pain assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — three independent animal models, myeloid-specific pathway placement, mechanistic cytokine signaling identified","pmids":["27320922"],"is_preprint":false},{"year":2017,"finding":"HIF1A transcriptionally upregulates ADORA2B expression on alternatively activated macrophages; HIF1A inhibition reduces ADORA2B expression on AAMs and disrupts AAM differentiation and IL-6 production, establishing HIF1A→ADORA2B as a regulatory axis in pulmonary fibrosis.","method":"HIF1A inhibitor in bleomycin mouse model, ADORA2B deletion/pharmacological antagonism, cultured macrophage differentiation assays, human IPF lung samples","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro mechanistic studies linking HIF1A to ADORA2B, single lab but multiple approaches","pmids":["28701304"],"is_preprint":false},{"year":2018,"finding":"ADORA2B signaling in pulmonary artery smooth muscle cells (PASMCs) mediates development of pulmonary hypertension through induction of IL-6, hyaluronan synthase 2 (HAS2), and tissue transglutaminase (Tgm2); ADORA2Bf/f-Taglncre mice were protected from PH development.","method":"ADORA2Bf/f-Taglncre conditional knockout mice, SUGEN/hypoxia and bleomycin PH models, RVSP measurement, Fulton index, vascular remodeling histology, RT-PCR in PASMCs","journal":"Frontiers in physiology","confidence":"High","confidence_rationale":"Tier 2 — PASMC-specific conditional KO with multiple cardiovascular and molecular phenotypic readouts","pmids":["29910735"],"is_preprint":false},{"year":2019,"finding":"APIP (Apaf-1-interacting protein) physically interacts with ADORA2B, stabilizing both proteins by interfering with lysosomal degradation, and activates downstream PKA-CREB signaling; knockdown of APIP impairs ADORA2B cytoprotective effects; the ADORA2B D296G variant (rs200741295) fails to bind APIP and loses cardioprotective activity.","method":"Co-immunoprecipitation, proximity ligation assay, APIP transgenic mice, Apip+/- mice, ADORA2B D296G knock-in mice, hypoxia cell death assays, AKT-HIF1α pathway analysis","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 — direct protein interaction by Co-IP and PLA, functional mutagenesis (D296G SNP), multiple genetic mouse models with in vitro and in vivo validation","pmids":["31263105"],"is_preprint":false},{"year":2020,"finding":"Hippocampal ADORA2B regulates Per2 expression and cognitive function; Adora2b-/- mice show reduced hippocampal PER2 protein and impaired T-maze alternation; ADORA2B agonist BAY-60-6583 restored midazolam-induced cognitive dysfunction and hippocampal Per2 levels; C-fos was downregulated in Adora2b-/- hippocampus.","method":"Adora2b-/- mice, midazolam treatment, BAY-60-6583 agonist administration, T-maze behavioral assay, hippocampal mRNA/protein expression analysis","journal":"Current pharmaceutical design","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with behavioral phenotype and molecular target (Per2, C-fos), pharmacologic rescue, single lab","pmids":["32294028"],"is_preprint":false},{"year":2021,"finding":"Neutrophil-derived netrin-1 is elevated during myocardial ischemia-reperfusion and attenuates cardiac injury through myeloid adenosine A2b receptor (ADORA2B) signaling, establishing an autocrine signaling loop between neutrophil netrin-1 and myeloid ADORA2B.","method":"Conditional netrin-1 deletion in neutrophils (Ntn1loxP/loxP Lyz2Cre+), neutrophil depletion, recombinant netrin-1 treatment, pharmacologic studies in myocardial I/R model, patient blood samples","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific conditional KO, pharmacologic studies, neutrophil depletion epistasis, patient clinical correlation","pmids":["33891683"],"is_preprint":false},{"year":2021,"finding":"CXCR4 and CXCR7 inhibition reduces platelet-neutrophil complex and NET formation through Adora2b signaling; protective effects of CXCR4/CXCR7 antagonism were abolished in Adora2b-/- mice, placing ADORA2B downstream of CXCR4/CXCR7 in inflammatory cell activation.","method":"Adora2b-/- mice, zymosan- and fecal-induced sepsis models, flow cytometry, histology, in vitro human platelet/PMN assays","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis with Adora2b-/- abolishing drug effect, in vitro human validation, single lab","pmids":["34948374"],"is_preprint":false},{"year":2023,"finding":"Myocyte-specific ENT1 limits cardioprotection by removing extracellular adenosine; ENT1 deletion in myocytes (Ent1loxP/loxP Myosin Cre+) reduced infarct sizes; cardioprotection from ENT inhibition required myeloid Adora2b signaling (abolished in Adora2bloxP/loxP LysM Cre+ mice), revealing a myocyte ENT1→extracellular adenosine→myeloid Adora2b axis.","method":"Tissue-specific conditional knockout mice (myocyte ENT1, myeloid Adora2b), dipyridamole treatment, cardiac adenosine level measurements, myocardial I/R model","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 — two independent tissue-specific conditional KO models with adenosine measurements and defined pathway placement","pmids":["37288658"],"is_preprint":false},{"year":2023,"finding":"CD73-dependent extracellular adenosine signals through Adora2b to mediate immunosuppression in pancreatic ductal adenocarcinoma; CD73 small-molecule inhibitors reduced tumor development, and Adora2b was identified as a determinant of adenosine-mediated immunosuppression.","method":"Genetically engineered and syngeneic mouse PDAC models, CD73 small-molecule inhibitors, multiplex immunofluorescence, HPLC adenosine measurement, transcriptomic analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo mouse tumor models with pharmacologic targeting, multiple analytical methods, single lab","pmids":["36720042"],"is_preprint":false},{"year":2021,"finding":"Long-term cigarette smoke extract exposure upregulates CD73 and ADORA2B expression, increases adenosine production, inhibits PKC alpha activity and p-ERK signaling, and impairs airway wound repair; knockdown of ADORA2B activates PKC alpha and restores p-ERK signaling, placing ADORA2B upstream of PKC alpha/ERK in chronic airway injury.","method":"Long-term CSE exposure cell model, ADORA2B and CD73 knockdown, PKC alpha and p-ERK assays, in vivo double knockout CD73/ADORA2B mice, wound closure assays","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo genetic manipulations with defined pathway, single lab","pmids":["33584346"],"is_preprint":false},{"year":2024,"finding":"ADORA2B promotes ferroptosis in chondrocytes by inhibiting the PI3K/Akt pathway; MYC acts as a transcriptional suppressor of ADORA2B (confirmed by dual-luciferase reporter and ChIP assays), and overexpression of ADORA2B reverses MYC-mediated protection from ferroptosis.","method":"ADORA2B knockdown/overexpression in chondrocytes, dual-luciferase reporter gene assay, ChIP assay, PI3K/Akt inhibitor (LY294002), MYC overexpression, in vivo OA mouse model","journal":"Environmental toxicology","confidence":"Medium","confidence_rationale":"Tier 1-2 — ChIP confirms direct transcriptional regulation; multiple orthogonal methods; single lab","pmids":["38174997"],"is_preprint":false},{"year":2025,"finding":"Caffeine inhibits ADORA2B signaling in red blood cells, impairing glycolytic flux and antioxidant defenses; Adora2b-deficient mice showed impaired glycolytic flux, compromised antioxidant defenses, and decreased transfusion efficacy; caffeine also directly inhibits recombinantly expressed G6PD.","method":"Adora2b-/- mouse model, murine storage/transfusion studies, recombinant G6PD inhibition assay, human donor cohort (13,091 donors), metabolomics","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 1-2 — reconstituted G6PD inhibition assay, genetic mouse model, large human cohort validation","pmids":["40905089"],"is_preprint":false},{"year":2023,"finding":"Dexmedetomidine alleviates pulmonary fibrosis by downregulating ADORA2B expression and suppressing ADORA2B-mediated MAPK pathway activation, thereby inhibiting myofibroblast differentiation; ADORA2B agonist (BAY60-6583) reversed the anti-fibrotic effects of dexmedetomidine.","method":"Bleomycin mouse model, TGF-β-induced myofibroblast model in vitro, MAPK pathway assays, BAY60-6583 agonist pharmacologic rescue","journal":"Respiratory research","confidence":"Medium","confidence_rationale":"Tier 3 — in vivo and in vitro with pharmacologic rescue, mechanism partially established, single lab","pmids":["37644529"],"is_preprint":false},{"year":2026,"finding":"ADORA2B activates the cAMP/PKA/PLB/SERCA2α signaling axis in cardiomyocytes; LA treatment activates ADORA2B leading to PKA-mediated phosphorylation of phospholamban, enhanced SERCA2α activity, and prevention of calcium overload; ADORA2B antagonist (MRS1754) partially reversed these effects.","method":"H9C2 cardiomyocyte H/R model, network pharmacology, ADORA2B antagonist (MRS1754), PKA/PLB/SERCA2α protein phosphorylation and expression assays, LDH/cTnI release assays","journal":"Current issues in molecular biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — cell-based mechanistic signaling cascade with pharmacologic antagonist validation, single lab, in vitro only","pmids":["41751389"],"is_preprint":false}],"current_model":"ADORA2B is a low-affinity adenosine G protein-coupled receptor that is transcriptionally induced by HIF1A during hypoxia/ischemia; it signals through cAMP/PKA and MAPK/CREB pathways to mediate tissue protection across multiple organs by stabilizing Per2 (which supports HIF-1α-dependent glycolysis in cardiomyocytes), suppressing PMN- and macrophage-dependent TNF-α and IL-6 release, enhancing regulatory T cell differentiation, promoting SERCA2α-dependent calcium homeostasis, and regulating red blood cell glycolytic metabolism, with its activity modulated by physical interaction with APIP (which prevents lysosomal degradation of ADORA2B) and by extracellular adenosine availability controlled by ENT transporters and CD73."},"narrative":{"teleology":[{"year":1995,"claim":"Establishing the genomic identity of human ADORA2B—chromosomal location (17p12) and gene structure with a coding-region intron—provided the foundational map for all subsequent molecular studies.","evidence":"FISH mapping and genomic cloning with partial sequencing","pmids":["7558011"],"confidence":"High","gaps":["Full promoter characterization not performed","No functional data from expression of cloned gene"]},{"year":2012,"claim":"Demonstration that ADORA2B stabilizes PER2 during myocardial ischemia, enabling a HIF-1α-dependent metabolic switch to oxygen-efficient glycolysis, revealed the first mechanistic link between adenosine signaling, circadian clock components, and ischemic cardioprotection.","evidence":"Adora2b−/− and Per2−/− mouse ischemic preconditioning models with metabolic profiling and glycolytic enzyme induction","pmids":["22504483"],"confidence":"High","gaps":["Direct biochemical mechanism of PER2 stabilization by ADORA2B not defined","Whether PER2 stabilization is cAMP-dependent or uses another second messenger"]},{"year":2012,"claim":"Reciprocal bone marrow transplants and neutrophil reconstitution experiments established that ADORA2B on myeloid cells—specifically PMNs—is the critical cell-type locus for suppressing TNF-α-dependent tissue injury in both cardiac and renal ischemia-reperfusion.","evidence":"WT↔Adora2b−/− bone marrow chimeras, neutrophil depletion/reconstitution with Tnf-α−/− neutrophils, myocardial and renal I/R models","pmids":["22531331","23028059"],"confidence":"High","gaps":["Intracellular signaling cascade from ADORA2B to TNF-α suppression in PMNs not delineated","Whether other myeloid subtypes beyond PMNs contribute"]},{"year":2012,"claim":"Showing that ADORA2B is required for adenosine-driven regulatory T cell differentiation extended its immunomodulatory role beyond innate immunity to adaptive immune tolerance.","evidence":"Adora2b−/− T cells in endotoxin-induced pulmonary inflammation with flow cytometric Treg quantification","pmids":["22389701"],"confidence":"Medium","gaps":["Whether ADORA2B acts cell-autonomously in T cells versus via antigen-presenting cells not fully resolved","Downstream transcription factor linking ADORA2B to FOXP3 induction unknown"]},{"year":2013,"claim":"Tissue-specific conditional knockouts revealed that ADORA2B operates through distinct cell-type circuits—alveolar epithelium in acute lung injury, vascular endothelium in diabetic nephropathy—establishing that its protective function is context- and compartment-specific.","evidence":"Alveolar-epithelial and endothelial-specific Adora2b conditional KO mice in ventilator-induced ALI and streptozotocin diabetic nephropathy models","pmids":["23603835","24262796"],"confidence":"High","gaps":["Whether epithelial versus endothelial ADORA2B engage the same second messenger cascades","Downstream targets in endothelial cells not identified"]},{"year":2013,"claim":"Identification of ADORA2B as a downstream effector of Fra-1 that promotes filopodia formation and invasive activity in breast cancer introduced a pro-tumorigenic dimension to ADORA2B biology.","evidence":"RNAi, pharmacologic antagonism, and in vivo xenograft lung metastasis assays","pmids":["23483055"],"confidence":"High","gaps":["Whether ADORA2B drives invasion through cAMP or an alternative G-protein pathway not established","Relevance to other cancer types unclear"]},{"year":2014,"claim":"Myeloid-specific ADORA2B deletion showed that on alternatively activated macrophages ADORA2B drives—rather than suppresses—pathological fibrosis and pulmonary hypertension via IL-6 and hyaluronan, revealing that ADORA2B's role switches from protective to pathogenic depending on chronicity and cell type.","evidence":"Adora2bf/f-LysMCre conditional KO mice in bleomycin lung fibrosis model with IL-6, CD206, arginase-1 readouts","pmids":["25318478"],"confidence":"High","gaps":["Signal that switches ADORA2B from anti-inflammatory to pro-fibrotic not identified","Whether receptor desensitization differs between acute and chronic contexts"]},{"year":2015,"claim":"Using three independent tissue-specific conditional knockouts in a single study definitively parsed ADORA2B's cardioprotective functions: endothelial and myocyte ADORA2B mediates preconditioning, while myeloid ADORA2B mediates post-ischemic protection.","evidence":"Lyz2-Cre, VE-cadherin-Cre, myosin-Cre × floxed Adora2b mice in myocardial I/R and ischemic preconditioning","pmids":["26136425"],"confidence":"High","gaps":["Distinct downstream effectors in each cell type not characterized","Whether preconditioning and reperfusion signals converge on PER2 unknown"]},{"year":2017,"claim":"Establishing that HIF-1α transcriptionally induces ADORA2B on macrophages created a feedforward HIF-1α→ADORA2B→IL-6 circuit, explaining how hypoxia amplifies macrophage-driven fibrosis.","evidence":"HIF-1α inhibition in bleomycin model plus macrophage differentiation assays and human IPF samples","pmids":["28701304"],"confidence":"Medium","gaps":["Whether HIF-1α directly binds ADORA2B promoter HREs not shown by ChIP","Single lab finding"]},{"year":2018,"claim":"PASMC-specific ADORA2B deletion protected from pulmonary hypertension and identified HAS2 and TGM2 as downstream effectors, extending ADORA2B's pathogenic fibrotic axis to smooth muscle cells beyond myeloid cells.","evidence":"Adora2bf/f-Taglncre conditional KO in SUGEN/hypoxia and bleomycin PH models with RVSP and vascular remodeling","pmids":["29910735"],"confidence":"High","gaps":["Whether cAMP or another pathway activates HAS2/TGM2 transcription not defined","Interaction with myeloid ADORA2B pathway unknown"]},{"year":2019,"claim":"Discovery that APIP physically interacts with ADORA2B and prevents its lysosomal degradation—and that the D296G variant disrupts this interaction and abolishes cardioprotection—provided the first post-translational regulatory mechanism for ADORA2B protein stability.","evidence":"Co-IP, proximity ligation assay, APIP transgenic/heterozygous KO mice, D296G knock-in mice, hypoxia assays","pmids":["31263105"],"confidence":"High","gaps":["Structural basis of APIP–ADORA2B interaction not resolved","Whether APIP modulates ADORA2B signaling kinetics beyond stability unknown"]},{"year":2021,"claim":"Identification of neutrophil-derived netrin-1 as an endogenous ligand-like activator of myeloid ADORA2B during myocardial I/R revealed an autocrine/paracrine loop that amplifies ADORA2B-dependent cardioprotection.","evidence":"Conditional netrin-1 deletion in neutrophils, recombinant netrin-1 rescue, myocardial I/R, patient samples","pmids":["33891683"],"confidence":"High","gaps":["Whether netrin-1 binds ADORA2B directly or acts through a co-receptor not determined","Relative contribution of netrin-1 versus adenosine to ADORA2B activation in vivo unclear"]},{"year":2023,"claim":"Genetic epistasis showed that myocyte ENT1 removes extracellular adenosine that otherwise activates myeloid ADORA2B, defining a complete intercellular signaling axis (myocyte ENT1 → adenosine pool → myeloid ADORA2B) controlling cardiac ischemic injury.","evidence":"Myocyte-specific ENT1 KO crossed with myeloid-specific Adora2b KO, cardiac adenosine measurements, I/R model","pmids":["37288658"],"confidence":"High","gaps":["Whether ENT2 has a compensatory role in myocytes not tested","Quantitative threshold of extracellular adenosine needed for ADORA2B activation unknown"]},{"year":2023,"claim":"CD73-derived adenosine signals through ADORA2B to mediate immunosuppression in pancreatic cancer, positioning the CD73-ADORA2B axis as a targetable immune checkpoint in the tumor microenvironment.","evidence":"Genetically engineered and syngeneic PDAC mouse models with CD73 inhibitors, HPLC adenosine measurement, transcriptomics","pmids":["36720042"],"confidence":"Medium","gaps":["Direct genetic ADORA2B deletion in tumor or immune compartment not performed","Which immune cell type mediates ADORA2B-dependent immunosuppression in PDAC not identified"]},{"year":2025,"claim":"Demonstration that ADORA2B regulates red blood cell glycolytic flux and antioxidant defenses—and that caffeine impairs this signaling—extended ADORA2B's metabolic regulatory role to erythrocyte biology and transfusion medicine.","evidence":"Adora2b−/− mice storage/transfusion studies, recombinant G6PD inhibition assay, metabolomics in 13,091 human donors","pmids":["40905089"],"confidence":"High","gaps":["Whether ADORA2B acts via cAMP in mature enucleated RBCs not fully confirmed","Direct protein interaction between ADORA2B signaling and G6PD not established"]},{"year":null,"claim":"Key unresolved questions include the structural basis of the APIP–ADORA2B interaction, the molecular switch that converts ADORA2B from tissue-protective to pro-fibrotic in chronic settings, and whether netrin-1 directly binds ADORA2B or requires a co-receptor.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of ADORA2B or ADORA2B–APIP complex","Mechanism of cell-type and context-dependent signaling polarity not defined","Netrin-1 binding mode to ADORA2B unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,3,6,9,15,25]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,12,14,21,22]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,15,7,25]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,3,8,12,17,20]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,8,14,20]}],"complexes":[],"partners":["APIP","PER2","NTN1","NT5E","SLC29A1","SLC29A2","HIF1A"],"other_free_text":[]},"mechanistic_narrative":"ADORA2B is a low-affinity G protein-coupled adenosine receptor that functions as a master tissue-protective signal transducer during hypoxia, ischemia, and inflammation across multiple organ systems. Upon activation by extracellular adenosine—whose availability is regulated by ENT transporters and CD73—ADORA2B signals through cAMP/PKA and MAPK/CREB pathways to stabilize the circadian protein PER2 (which supports HIF-1α-dependent glycolytic metabolism in cardiomyocytes and hippocampal neurons), suppress neutrophil and macrophage TNF-α and IL-6 release, enhance regulatory T cell differentiation, activate SERCA2α-dependent calcium homeostasis, and regulate red blood cell glycolytic flux and antioxidant defenses [PMID:22504483, PMID:22531331, PMID:22389701, PMID:26136425, PMID:41751389, PMID:40905089]. ADORA2B expression is transcriptionally induced by HIF-1α during hypoxia and its protein stability is maintained through physical interaction with APIP, which prevents lysosomal degradation; the D296G variant that disrupts APIP binding abolishes cardioprotective activity [PMID:28701304, PMID:31263105]. Cell-type-specific functions are prominent: myeloid ADORA2B constrains neutrophil-dependent inflammation in cardiac and renal ischemia-reperfusion injury but drives alternatively activated macrophage-dependent pulmonary fibrosis and hypertension through IL-6 and hyaluronan production, while on pulmonary artery smooth muscle cells it induces vascular remodeling mediators including HAS2 and TGM2 [PMID:23028059, PMID:25318478, PMID:29910735, PMID:27320922]."},"prefetch_data":{"uniprot":{"accession":"P29275","full_name":"Adenosine receptor A2b","aliases":[],"length_aa":332,"mass_kda":36.3,"function":"Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P29275/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADORA2B","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADORA2B","total_profiled":1310},"omim":[{"mim_id":"608099","title":"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3","url":"https://www.omim.org/entry/608099"},{"mim_id":"601614","title":"NETRIN 1; NTN1","url":"https://www.omim.org/entry/601614"},{"mim_id":"600446","title":"ADENOSINE A2B RECEPTOR; ADORA2B","url":"https://www.omim.org/entry/600446"},{"mim_id":"600445","title":"ADENOSINE A3 RECEPTOR; ADORA3","url":"https://www.omim.org/entry/600445"},{"mim_id":"600119","title":"SARCOGLYCAN, ALPHA; SGCA","url":"https://www.omim.org/entry/600119"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":12.5},{"tissue":"urinary bladder","ntpm":15.6}],"url":"https://www.proteinatlas.org/search/ADORA2B"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P29275","domains":[{"cath_id":"1.20.1070.10","chopping":"6-151_168-310","consensus_level":"high","plddt":93.9677,"start":6,"end":310}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29275","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29275-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29275-F1-predicted_aligned_error_v6.png","plddt_mean":88.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADORA2B","jax_strain_url":"https://www.jax.org/strain/search?query=ADORA2B"},"sequence":{"accession":"P29275","fasta_url":"https://rest.uniprot.org/uniprotkb/P29275.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29275/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29275"}},"corpus_meta":[{"pmid":"22504483","id":"PMC_22504483","title":"Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22504483","citation_count":271,"is_preprint":false},{"pmid":"23483055","id":"PMC_23483055","title":"Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23483055","citation_count":145,"is_preprint":false},{"pmid":"23603835","id":"PMC_23603835","title":"Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury.","date":"2013","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/23603835","citation_count":93,"is_preprint":false},{"pmid":"22389701","id":"PMC_22389701","title":"Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22389701","citation_count":90,"is_preprint":false},{"pmid":"25318478","id":"PMC_25318478","title":"Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25318478","citation_count":67,"is_preprint":false},{"pmid":"28701304","id":"PMC_28701304","title":"HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28701304","citation_count":63,"is_preprint":false},{"pmid":"27320922","id":"PMC_27320922","title":"Sustained Elevated Adenosine via ADORA2B Promotes Chronic Pain through Neuro-immune Interaction.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27320922","citation_count":58,"is_preprint":false},{"pmid":"22531331","id":"PMC_22531331","title":"Adora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury.","date":"2012","source":"Anesthesiology","url":"https://pubmed.ncbi.nlm.nih.gov/22531331","citation_count":42,"is_preprint":false},{"pmid":"24262796","id":"PMC_24262796","title":"CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy.","date":"2013","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/24262796","citation_count":41,"is_preprint":false},{"pmid":"33891683","id":"PMC_33891683","title":"PMN-derived netrin-1 attenuates cardiac ischemia-reperfusion injury via myeloid ADORA2B signaling.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33891683","citation_count":39,"is_preprint":false},{"pmid":"23028059","id":"PMC_23028059","title":"Adora2b adenosine receptor signaling protects during acute kidney injury via inhibition of neutrophil-dependent TNF-α release.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23028059","citation_count":39,"is_preprint":false},{"pmid":"36720042","id":"PMC_36720042","title":"CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36720042","citation_count":35,"is_preprint":false},{"pmid":"7558011","id":"PMC_7558011","title":"Cloning and chromosomal localization of the human A2b adenosine receptor gene (ADORA2B) and its pseudogene.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7558011","citation_count":35,"is_preprint":false},{"pmid":"26136425","id":"PMC_26136425","title":"Differential Tissue-Specific Function of Adora2b in Cardioprotection.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26136425","citation_count":34,"is_preprint":false},{"pmid":"29910735","id":"PMC_29910735","title":"Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension.","date":"2018","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29910735","citation_count":23,"is_preprint":false},{"pmid":"23638125","id":"PMC_23638125","title":"The stimulatory adenosine receptor ADORA2B regulates serotonin (5-HT) synthesis and release in oxygen-depleted EC cells in inflammatory bowel disease.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23638125","citation_count":21,"is_preprint":false},{"pmid":"37187740","id":"PMC_37187740","title":"The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37187740","citation_count":20,"is_preprint":false},{"pmid":"27404219","id":"PMC_27404219","title":"Adenosine Receptor Adora2b Plays a Mechanistic Role in the Protective Effect of the Volatile Anesthetic Sevoflurane during Liver Ischemia/Reperfusion.","date":"2016","source":"Anesthesiology","url":"https://pubmed.ncbi.nlm.nih.gov/27404219","citation_count":20,"is_preprint":false},{"pmid":"34948374","id":"PMC_34948374","title":"CXCR4 and CXCR7 Inhibition Ameliorates the Formation of Platelet-Neutrophil Complexes and Neutrophil Extracellular Traps through Adora2b Signaling.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34948374","citation_count":19,"is_preprint":false},{"pmid":"25629231","id":"PMC_25629231","title":"The association of ADORA2A and ADORA2B polymorphisms with the risk and severity of chronic heart failure: a case-control study of a northern Chinese population.","date":"2015","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25629231","citation_count":19,"is_preprint":false},{"pmid":"35910389","id":"PMC_35910389","title":"Alternative adenosine Receptor activation: The netrin-Adora2b link.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35910389","citation_count":17,"is_preprint":false},{"pmid":"37288658","id":"PMC_37288658","title":"Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/37288658","citation_count":16,"is_preprint":false},{"pmid":"31263105","id":"PMC_31263105","title":"Cardioprotective role of APIP in myocardial infarction through ADORA2B.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31263105","citation_count":14,"is_preprint":false},{"pmid":"27747290","id":"PMC_27747290","title":"ADORA2b Signaling in Cardioprotection.","date":"2016","source":"Journal of nature and science","url":"https://pubmed.ncbi.nlm.nih.gov/27747290","citation_count":12,"is_preprint":false},{"pmid":"37644529","id":"PMC_37644529","title":"Dexmedetomidine alleviates pulmonary fibrosis through the ADORA2B-Mediated MAPK signaling pathway.","date":"2023","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/37644529","citation_count":8,"is_preprint":false},{"pmid":"38174997","id":"PMC_38174997","title":"ADORA2B, transcriptionally suppressing by MYC, promotes ferroptosis of chondrocytes via inhibition of the PI3K/Akt pathway in mice with osteoarthritis.","date":"2024","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38174997","citation_count":8,"is_preprint":false},{"pmid":"33584346","id":"PMC_33584346","title":"Co-inhibition of CD73 and ADORA2B Improves Long-Term Cigarette Smoke Induced Lung Injury.","date":"2021","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33584346","citation_count":7,"is_preprint":false},{"pmid":"32294028","id":"PMC_32294028","title":"A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction.","date":"2020","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/32294028","citation_count":6,"is_preprint":false},{"pmid":"32122590","id":"PMC_32122590","title":"Adenosine receptor Adora2b antagonism attenuates Brucella abortus 544 infection in professional phagocyte RAW 264.7 cells and BALB/c mice.","date":"2020","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32122590","citation_count":6,"is_preprint":false},{"pmid":"38070193","id":"PMC_38070193","title":"Salvianolic acid B attenuates diabetic nephropathy through alleviating ADORA2B, NALP3 in flammasome, and NFκB activity.","date":"2023","source":"Canadian journal of physiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38070193","citation_count":5,"is_preprint":false},{"pmid":"31985456","id":"PMC_31985456","title":"Does ischemic preconditioning increase flap survival by ADORA2B receptor activation?","date":"2020","source":"Clinical hemorheology and microcirculation","url":"https://pubmed.ncbi.nlm.nih.gov/31985456","citation_count":5,"is_preprint":false},{"pmid":"40905089","id":"PMC_40905089","title":"Caffeine impairs red blood cell storage quality by dual inhibition of ADORA2b signaling and G6PD activity.","date":"2025","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/40905089","citation_count":3,"is_preprint":false},{"pmid":"17822556","id":"PMC_17822556","title":"The promoter regions of the Myb-regulated Adora2B and Mcm4 genes co-localize with origins of DNA replication.","date":"2007","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17822556","citation_count":2,"is_preprint":false},{"pmid":"39995546","id":"PMC_39995546","title":"Ghrelin suppresses apoptosis and autophagy in osteoarthritis synovial cells by modulating the ADORA2B/PI3K/Akt/mTOR signaling pathway.","date":"2025","source":"Journal of orthopaedics","url":"https://pubmed.ncbi.nlm.nih.gov/39995546","citation_count":1,"is_preprint":false},{"pmid":"40389870","id":"PMC_40389870","title":"To verify the biological characteristics of disulfidptosis associated gene ADORA2B in esophageal cancer.","date":"2025","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/40389870","citation_count":1,"is_preprint":false},{"pmid":"41346607","id":"PMC_41346607","title":"Potential of Adora2b as an immunotherapeutic target for gastric cancer.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41346607","citation_count":0,"is_preprint":false},{"pmid":"40502093","id":"PMC_40502093","title":"Caffeine Impairs Red Blood Cell Storage Quality by Dual Inhibition of ADORA2b Signaling and G6PD Activity.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40502093","citation_count":0,"is_preprint":false},{"pmid":"41751389","id":"PMC_41751389","title":"Levistolide A Alleviates Myocardial Ischemia-Reperfusion Injury Partly by Improving Calcium Homeostasis via the ADORA2B/cAMP/PKA/PLB/SERCA2α Signaling Axis.","date":"2026","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/41751389","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":22181,"output_tokens":6405,"usd":0.081309},"stage2":{"model":"claude-opus-4-6","input_tokens":10087,"output_tokens":7716,"usd":0.365003},"total_usd":0.446312,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"Adora2b signaling during myocardial ischemia leads to stabilization of the circadian rhythm protein Per2, which in turn stabilizes HIF-1α, enabling a HIF-dependent metabolic switch to oxygen-efficient glycolysis that is cardioprotective; Per2-/- mice lack this metabolic shift and have larger infarct sizes.\",\n      \"method\": \"Genetic knockout mice (Adora2b-/-, Per2-/-), metabolic studies, ischemic preconditioning model, light-induced Per2 stabilization with transcriptional induction of glycolytic enzymes\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genetic models and functional metabolic readouts, replicated across multiple experimental conditions\",\n      \"pmids\": [\"22504483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Adora2b signaling on bone marrow-derived cells, specifically polymorphonuclear neutrophils (PMNs), dampens myocardial ischemia-reperfusion injury by suppressing TNF-α release from PMNs.\",\n      \"method\": \"Bone marrow transplantation between WT and Adora2b-/- mice, neutrophil depletion, Adora2b agonist treatment, cytokine profiling, pharmacologic studies on human activated PMNs\",\n      \"journal\": \"Anesthesiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal bone marrow transplant experiments plus neutrophil depletion and pharmacologic validation in human cells\",\n      \"pmids\": [\"22531331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Adora2b signaling on T cells enhances regulatory T cell (Treg) differentiation; Adora2b-/- T cells fail to differentiate into Tregs upon adenosine receptor activation, and Adora2b-deficient mice exhibit more severe endotoxin-induced pulmonary inflammation with impaired Treg induction.\",\n      \"method\": \"Pharmacologic Adora2b activation, Adora2b-/- mice, endotoxin-induced pulmonary inflammation model, flow cytometry for T cell subsets\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined cellular phenotype, single lab\",\n      \"pmids\": [\"22389701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Adora2b signaling on neutrophils constrains TNF-α production during renal ischemia-reperfusion; reconstitution of Adora2b-/- mice with TNF-α-deficient neutrophils rescued the injury phenotype, placing Adora2b upstream of neutrophil-dependent TNF-α in acute kidney injury.\",\n      \"method\": \"Adora2b-/- mice, TNF-α antibody blockade, Tnf-α-/- mice, neutrophil depletion and reconstitution, renal ischemia-reperfusion model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via adoptive transfer/reconstitution plus multiple loss-of-function models with defined phenotype\",\n      \"pmids\": [\"23028059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Alveolar epithelial Adora2b signaling mediates ENT2-dependent lung protection during acute lung injury; dipyridamole-dependent attenuation of lung inflammation was abolished in mice with alveolar epithelial Adora2b deletion, establishing a crosstalk pathway between ENT2 and Adora2b.\",\n      \"method\": \"Ent1-/-, Ent2-/- gene-targeted mice, tissue-specific Adora2b deletion in alveolar epithelium, dipyridamole treatment, mechanical ventilation-induced ALI model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific conditional KO plus pharmacologic rescue with defined pulmonary phenotype\",\n      \"pmids\": [\"23603835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADORA2B signaling in breast cancer cells downstream of Fra-1 transcription factor promotes filopodia formation and invasive activity; RNAi silencing or pharmacologic blockade of ADORA2B inhibited filopodia formation, invasion in vitro, and tumor outgrowth in lungs in vivo.\",\n      \"method\": \"Stable RNAi depletion, pharmacologic ADORA2B antagonism, in vivo xenograft metastasis assays, synthetic lethal drug screen\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vivo and in vitro orthogonal methods; Fra-1→ADORA2B axis established by RNAi and pharmacology\",\n      \"pmids\": [\"23483055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADORA2B signaling on vascular endothelium mediates protection from diabetic nephropathy; tissue-specific deletion of Adora2b in vascular endothelia (but not tubular epithelia) worsened nephropathy, and selective Adora2b agonist treatment was protective.\",\n      \"method\": \"Tissue-specific conditional knockout mice (endothelial vs. tubular), streptozotocin diabetic model, transgenic Adora2b reporter mice, selective agonist (BAY 60-6583) treatment\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific conditional KO with pharmacologic validation, multiple orthogonal approaches\",\n      \"pmids\": [\"24262796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADORA2B acts as a mechanoreceptor in enterochromaffin (EC) cells; under hypoxia, ADORA2B activates HIF-1α signaling via MAPK/CREB pathways and phosphorylates TPH-1 and activates VMAT-1 to stimulate serotonin (5-HT) synthesis and secretion.\",\n      \"method\": \"Hypoxia experiments on EC cells and IBD mucosa, antisense knockdown, NECA agonist, MRS1754 antagonist, Renilla luciferase under HRE control, PCR/western blot\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in cell model, antisense mechanistic confirmation, single lab\",\n      \"pmids\": [\"23638125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ADORA2B signaling on myeloid cells (alternatively activated macrophages) drives lung fibrosis and pulmonary hypertension; conditional deletion of ADORA2B on myeloid cells attenuated fibrosis and PH with reduced IL-6, hyaluronan, CD206, and arginase-1.\",\n      \"method\": \"Conditional knockout mice (Adora2Bf/f-LysMCre), bleomycin-induced lung injury model, bronchoalveolar lavage, histology, lung function measurements\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific conditional KO with multiple molecular and physiological readouts\",\n      \"pmids\": [\"25318478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADORA2B mediates different cardioprotective mechanisms in a tissue-specific manner: endothelial and myocyte Adora2b mediates ischemic preconditioning, while inflammatory cell (PMN) Adora2b is required for protection from ischemia-reperfusion injury; adoptive transfer of Adora2b-/- PMNs confirmed the PMN-specific role.\",\n      \"method\": \"Tissue-specific conditional knockout mice (Lyz2-Cre, VE-cadherin-Cre, myosin-Cre crossed to floxed Adora2b), myocardial I/R and IP models, cytokine profiling, adoptive PMN transfer\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three independent tissue-specific conditional KO lines plus adoptive transfer, multiple orthogonal readouts\",\n      \"pmids\": [\"26136425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The human ADORA2B gene is located on chromosome 17p12; its pseudogene maps to chromosome 1q32. Partial sequence revealed an intron interrupting the coding region at the second intracellular loop, similar to A1 and A2a adenosine receptor genes.\",\n      \"method\": \"Fluorescence in situ hybridization (FISH), genomic cloning, partial sequence analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural/genomic characterization by FISH and sequencing, foundational paper\",\n      \"pmids\": [\"7558011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sevoflurane's hepatoprotective effects during liver ischemia-reperfusion require Adora2b signaling; sevoflurane inhibited platelet-neutrophil complex formation and reduced liver damage in wild-type but not Adora2b-/- mice, and increased Adora2b transcription and expression in liver tissue.\",\n      \"method\": \"Adora2b-/- and Adora2a-/- mice, liver IR model, flow cytometry, immunohistochemistry, real-time PCR, ex vivo human blood experiments\",\n      \"journal\": \"Anesthesiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — global KO with functional phenotype and molecular readout, single lab\",\n      \"pmids\": [\"27404219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sustained activation of adenosine A2B receptors on myeloid cells promotes chronic pain by inducing nociceptor hyperexcitability via soluble IL-6 receptor trans-signaling; this mechanism was demonstrated in ADA-deficient mice, sickle cell disease mice, and CFA inflammatory pain models.\",\n      \"method\": \"Ada-/- mice, sickle cell disease mouse model, CFA inflammatory pain model, myeloid-specific ADORA2B manipulation, behavioral pain assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three independent animal models, myeloid-specific pathway placement, mechanistic cytokine signaling identified\",\n      \"pmids\": [\"27320922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HIF1A transcriptionally upregulates ADORA2B expression on alternatively activated macrophages; HIF1A inhibition reduces ADORA2B expression on AAMs and disrupts AAM differentiation and IL-6 production, establishing HIF1A→ADORA2B as a regulatory axis in pulmonary fibrosis.\",\n      \"method\": \"HIF1A inhibitor in bleomycin mouse model, ADORA2B deletion/pharmacological antagonism, cultured macrophage differentiation assays, human IPF lung samples\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro mechanistic studies linking HIF1A to ADORA2B, single lab but multiple approaches\",\n      \"pmids\": [\"28701304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ADORA2B signaling in pulmonary artery smooth muscle cells (PASMCs) mediates development of pulmonary hypertension through induction of IL-6, hyaluronan synthase 2 (HAS2), and tissue transglutaminase (Tgm2); ADORA2Bf/f-Taglncre mice were protected from PH development.\",\n      \"method\": \"ADORA2Bf/f-Taglncre conditional knockout mice, SUGEN/hypoxia and bleomycin PH models, RVSP measurement, Fulton index, vascular remodeling histology, RT-PCR in PASMCs\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — PASMC-specific conditional KO with multiple cardiovascular and molecular phenotypic readouts\",\n      \"pmids\": [\"29910735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"APIP (Apaf-1-interacting protein) physically interacts with ADORA2B, stabilizing both proteins by interfering with lysosomal degradation, and activates downstream PKA-CREB signaling; knockdown of APIP impairs ADORA2B cytoprotective effects; the ADORA2B D296G variant (rs200741295) fails to bind APIP and loses cardioprotective activity.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, APIP transgenic mice, Apip+/- mice, ADORA2B D296G knock-in mice, hypoxia cell death assays, AKT-HIF1α pathway analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct protein interaction by Co-IP and PLA, functional mutagenesis (D296G SNP), multiple genetic mouse models with in vitro and in vivo validation\",\n      \"pmids\": [\"31263105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Hippocampal ADORA2B regulates Per2 expression and cognitive function; Adora2b-/- mice show reduced hippocampal PER2 protein and impaired T-maze alternation; ADORA2B agonist BAY-60-6583 restored midazolam-induced cognitive dysfunction and hippocampal Per2 levels; C-fos was downregulated in Adora2b-/- hippocampus.\",\n      \"method\": \"Adora2b-/- mice, midazolam treatment, BAY-60-6583 agonist administration, T-maze behavioral assay, hippocampal mRNA/protein expression analysis\",\n      \"journal\": \"Current pharmaceutical design\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with behavioral phenotype and molecular target (Per2, C-fos), pharmacologic rescue, single lab\",\n      \"pmids\": [\"32294028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Neutrophil-derived netrin-1 is elevated during myocardial ischemia-reperfusion and attenuates cardiac injury through myeloid adenosine A2b receptor (ADORA2B) signaling, establishing an autocrine signaling loop between neutrophil netrin-1 and myeloid ADORA2B.\",\n      \"method\": \"Conditional netrin-1 deletion in neutrophils (Ntn1loxP/loxP Lyz2Cre+), neutrophil depletion, recombinant netrin-1 treatment, pharmacologic studies in myocardial I/R model, patient blood samples\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific conditional KO, pharmacologic studies, neutrophil depletion epistasis, patient clinical correlation\",\n      \"pmids\": [\"33891683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CXCR4 and CXCR7 inhibition reduces platelet-neutrophil complex and NET formation through Adora2b signaling; protective effects of CXCR4/CXCR7 antagonism were abolished in Adora2b-/- mice, placing ADORA2B downstream of CXCR4/CXCR7 in inflammatory cell activation.\",\n      \"method\": \"Adora2b-/- mice, zymosan- and fecal-induced sepsis models, flow cytometry, histology, in vitro human platelet/PMN assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with Adora2b-/- abolishing drug effect, in vitro human validation, single lab\",\n      \"pmids\": [\"34948374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Myocyte-specific ENT1 limits cardioprotection by removing extracellular adenosine; ENT1 deletion in myocytes (Ent1loxP/loxP Myosin Cre+) reduced infarct sizes; cardioprotection from ENT inhibition required myeloid Adora2b signaling (abolished in Adora2bloxP/loxP LysM Cre+ mice), revealing a myocyte ENT1→extracellular adenosine→myeloid Adora2b axis.\",\n      \"method\": \"Tissue-specific conditional knockout mice (myocyte ENT1, myeloid Adora2b), dipyridamole treatment, cardiac adenosine level measurements, myocardial I/R model\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent tissue-specific conditional KO models with adenosine measurements and defined pathway placement\",\n      \"pmids\": [\"37288658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CD73-dependent extracellular adenosine signals through Adora2b to mediate immunosuppression in pancreatic ductal adenocarcinoma; CD73 small-molecule inhibitors reduced tumor development, and Adora2b was identified as a determinant of adenosine-mediated immunosuppression.\",\n      \"method\": \"Genetically engineered and syngeneic mouse PDAC models, CD73 small-molecule inhibitors, multiplex immunofluorescence, HPLC adenosine measurement, transcriptomic analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse tumor models with pharmacologic targeting, multiple analytical methods, single lab\",\n      \"pmids\": [\"36720042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Long-term cigarette smoke extract exposure upregulates CD73 and ADORA2B expression, increases adenosine production, inhibits PKC alpha activity and p-ERK signaling, and impairs airway wound repair; knockdown of ADORA2B activates PKC alpha and restores p-ERK signaling, placing ADORA2B upstream of PKC alpha/ERK in chronic airway injury.\",\n      \"method\": \"Long-term CSE exposure cell model, ADORA2B and CD73 knockdown, PKC alpha and p-ERK assays, in vivo double knockout CD73/ADORA2B mice, wound closure assays\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo genetic manipulations with defined pathway, single lab\",\n      \"pmids\": [\"33584346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADORA2B promotes ferroptosis in chondrocytes by inhibiting the PI3K/Akt pathway; MYC acts as a transcriptional suppressor of ADORA2B (confirmed by dual-luciferase reporter and ChIP assays), and overexpression of ADORA2B reverses MYC-mediated protection from ferroptosis.\",\n      \"method\": \"ADORA2B knockdown/overexpression in chondrocytes, dual-luciferase reporter gene assay, ChIP assay, PI3K/Akt inhibitor (LY294002), MYC overexpression, in vivo OA mouse model\",\n      \"journal\": \"Environmental toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP confirms direct transcriptional regulation; multiple orthogonal methods; single lab\",\n      \"pmids\": [\"38174997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Caffeine inhibits ADORA2B signaling in red blood cells, impairing glycolytic flux and antioxidant defenses; Adora2b-deficient mice showed impaired glycolytic flux, compromised antioxidant defenses, and decreased transfusion efficacy; caffeine also directly inhibits recombinantly expressed G6PD.\",\n      \"method\": \"Adora2b-/- mouse model, murine storage/transfusion studies, recombinant G6PD inhibition assay, human donor cohort (13,091 donors), metabolomics\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted G6PD inhibition assay, genetic mouse model, large human cohort validation\",\n      \"pmids\": [\"40905089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Dexmedetomidine alleviates pulmonary fibrosis by downregulating ADORA2B expression and suppressing ADORA2B-mediated MAPK pathway activation, thereby inhibiting myofibroblast differentiation; ADORA2B agonist (BAY60-6583) reversed the anti-fibrotic effects of dexmedetomidine.\",\n      \"method\": \"Bleomycin mouse model, TGF-β-induced myofibroblast model in vitro, MAPK pathway assays, BAY60-6583 agonist pharmacologic rescue\",\n      \"journal\": \"Respiratory research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — in vivo and in vitro with pharmacologic rescue, mechanism partially established, single lab\",\n      \"pmids\": [\"37644529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ADORA2B activates the cAMP/PKA/PLB/SERCA2α signaling axis in cardiomyocytes; LA treatment activates ADORA2B leading to PKA-mediated phosphorylation of phospholamban, enhanced SERCA2α activity, and prevention of calcium overload; ADORA2B antagonist (MRS1754) partially reversed these effects.\",\n      \"method\": \"H9C2 cardiomyocyte H/R model, network pharmacology, ADORA2B antagonist (MRS1754), PKA/PLB/SERCA2α protein phosphorylation and expression assays, LDH/cTnI release assays\",\n      \"journal\": \"Current issues in molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — cell-based mechanistic signaling cascade with pharmacologic antagonist validation, single lab, in vitro only\",\n      \"pmids\": [\"41751389\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADORA2B is a low-affinity adenosine G protein-coupled receptor that is transcriptionally induced by HIF1A during hypoxia/ischemia; it signals through cAMP/PKA and MAPK/CREB pathways to mediate tissue protection across multiple organs by stabilizing Per2 (which supports HIF-1α-dependent glycolysis in cardiomyocytes), suppressing PMN- and macrophage-dependent TNF-α and IL-6 release, enhancing regulatory T cell differentiation, promoting SERCA2α-dependent calcium homeostasis, and regulating red blood cell glycolytic metabolism, with its activity modulated by physical interaction with APIP (which prevents lysosomal degradation of ADORA2B) and by extracellular adenosine availability controlled by ENT transporters and CD73.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ADORA2B is a low-affinity G protein-coupled adenosine receptor that functions as a master tissue-protective signal transducer during hypoxia, ischemia, and inflammation across multiple organ systems. Upon activation by extracellular adenosine—whose availability is regulated by ENT transporters and CD73—ADORA2B signals through cAMP/PKA and MAPK/CREB pathways to stabilize the circadian protein PER2 (which supports HIF-1α-dependent glycolytic metabolism in cardiomyocytes and hippocampal neurons), suppress neutrophil and macrophage TNF-α and IL-6 release, enhance regulatory T cell differentiation, activate SERCA2α-dependent calcium homeostasis, and regulate red blood cell glycolytic flux and antioxidant defenses [PMID:22504483, PMID:22531331, PMID:22389701, PMID:26136425, PMID:41751389, PMID:40905089]. ADORA2B expression is transcriptionally induced by HIF-1α during hypoxia and its protein stability is maintained through physical interaction with APIP, which prevents lysosomal degradation; the D296G variant that disrupts APIP binding abolishes cardioprotective activity [PMID:28701304, PMID:31263105]. Cell-type-specific functions are prominent: myeloid ADORA2B constrains neutrophil-dependent inflammation in cardiac and renal ischemia-reperfusion injury but drives alternatively activated macrophage-dependent pulmonary fibrosis and hypertension through IL-6 and hyaluronan production, while on pulmonary artery smooth muscle cells it induces vascular remodeling mediators including HAS2 and TGM2 [PMID:23028059, PMID:25318478, PMID:29910735, PMID:27320922].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing the genomic identity of human ADORA2B—chromosomal location (17p12) and gene structure with a coding-region intron—provided the foundational map for all subsequent molecular studies.\",\n      \"evidence\": \"FISH mapping and genomic cloning with partial sequencing\",\n      \"pmids\": [\"7558011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full promoter characterization not performed\", \"No functional data from expression of cloned gene\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstration that ADORA2B stabilizes PER2 during myocardial ischemia, enabling a HIF-1α-dependent metabolic switch to oxygen-efficient glycolysis, revealed the first mechanistic link between adenosine signaling, circadian clock components, and ischemic cardioprotection.\",\n      \"evidence\": \"Adora2b−/− and Per2−/− mouse ischemic preconditioning models with metabolic profiling and glycolytic enzyme induction\",\n      \"pmids\": [\"22504483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical mechanism of PER2 stabilization by ADORA2B not defined\", \"Whether PER2 stabilization is cAMP-dependent or uses another second messenger\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Reciprocal bone marrow transplants and neutrophil reconstitution experiments established that ADORA2B on myeloid cells—specifically PMNs—is the critical cell-type locus for suppressing TNF-α-dependent tissue injury in both cardiac and renal ischemia-reperfusion.\",\n      \"evidence\": \"WT↔Adora2b−/− bone marrow chimeras, neutrophil depletion/reconstitution with Tnf-α−/− neutrophils, myocardial and renal I/R models\",\n      \"pmids\": [\"22531331\", \"23028059\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling cascade from ADORA2B to TNF-α suppression in PMNs not delineated\", \"Whether other myeloid subtypes beyond PMNs contribute\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showing that ADORA2B is required for adenosine-driven regulatory T cell differentiation extended its immunomodulatory role beyond innate immunity to adaptive immune tolerance.\",\n      \"evidence\": \"Adora2b−/− T cells in endotoxin-induced pulmonary inflammation with flow cytometric Treg quantification\",\n      \"pmids\": [\"22389701\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ADORA2B acts cell-autonomously in T cells versus via antigen-presenting cells not fully resolved\", \"Downstream transcription factor linking ADORA2B to FOXP3 induction unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Tissue-specific conditional knockouts revealed that ADORA2B operates through distinct cell-type circuits—alveolar epithelium in acute lung injury, vascular endothelium in diabetic nephropathy—establishing that its protective function is context- and compartment-specific.\",\n      \"evidence\": \"Alveolar-epithelial and endothelial-specific Adora2b conditional KO mice in ventilator-induced ALI and streptozotocin diabetic nephropathy models\",\n      \"pmids\": [\"23603835\", \"24262796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether epithelial versus endothelial ADORA2B engage the same second messenger cascades\", \"Downstream targets in endothelial cells not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of ADORA2B as a downstream effector of Fra-1 that promotes filopodia formation and invasive activity in breast cancer introduced a pro-tumorigenic dimension to ADORA2B biology.\",\n      \"evidence\": \"RNAi, pharmacologic antagonism, and in vivo xenograft lung metastasis assays\",\n      \"pmids\": [\"23483055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ADORA2B drives invasion through cAMP or an alternative G-protein pathway not established\", \"Relevance to other cancer types unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Myeloid-specific ADORA2B deletion showed that on alternatively activated macrophages ADORA2B drives—rather than suppresses—pathological fibrosis and pulmonary hypertension via IL-6 and hyaluronan, revealing that ADORA2B's role switches from protective to pathogenic depending on chronicity and cell type.\",\n      \"evidence\": \"Adora2bf/f-LysMCre conditional KO mice in bleomycin lung fibrosis model with IL-6, CD206, arginase-1 readouts\",\n      \"pmids\": [\"25318478\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal that switches ADORA2B from anti-inflammatory to pro-fibrotic not identified\", \"Whether receptor desensitization differs between acute and chronic contexts\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Using three independent tissue-specific conditional knockouts in a single study definitively parsed ADORA2B's cardioprotective functions: endothelial and myocyte ADORA2B mediates preconditioning, while myeloid ADORA2B mediates post-ischemic protection.\",\n      \"evidence\": \"Lyz2-Cre, VE-cadherin-Cre, myosin-Cre × floxed Adora2b mice in myocardial I/R and ischemic preconditioning\",\n      \"pmids\": [\"26136425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distinct downstream effectors in each cell type not characterized\", \"Whether preconditioning and reperfusion signals converge on PER2 unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Establishing that HIF-1α transcriptionally induces ADORA2B on macrophages created a feedforward HIF-1α→ADORA2B→IL-6 circuit, explaining how hypoxia amplifies macrophage-driven fibrosis.\",\n      \"evidence\": \"HIF-1α inhibition in bleomycin model plus macrophage differentiation assays and human IPF samples\",\n      \"pmids\": [\"28701304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether HIF-1α directly binds ADORA2B promoter HREs not shown by ChIP\", \"Single lab finding\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"PASMC-specific ADORA2B deletion protected from pulmonary hypertension and identified HAS2 and TGM2 as downstream effectors, extending ADORA2B's pathogenic fibrotic axis to smooth muscle cells beyond myeloid cells.\",\n      \"evidence\": \"Adora2bf/f-Taglncre conditional KO in SUGEN/hypoxia and bleomycin PH models with RVSP and vascular remodeling\",\n      \"pmids\": [\"29910735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cAMP or another pathway activates HAS2/TGM2 transcription not defined\", \"Interaction with myeloid ADORA2B pathway unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that APIP physically interacts with ADORA2B and prevents its lysosomal degradation—and that the D296G variant disrupts this interaction and abolishes cardioprotection—provided the first post-translational regulatory mechanism for ADORA2B protein stability.\",\n      \"evidence\": \"Co-IP, proximity ligation assay, APIP transgenic/heterozygous KO mice, D296G knock-in mice, hypoxia assays\",\n      \"pmids\": [\"31263105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of APIP–ADORA2B interaction not resolved\", \"Whether APIP modulates ADORA2B signaling kinetics beyond stability unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of neutrophil-derived netrin-1 as an endogenous ligand-like activator of myeloid ADORA2B during myocardial I/R revealed an autocrine/paracrine loop that amplifies ADORA2B-dependent cardioprotection.\",\n      \"evidence\": \"Conditional netrin-1 deletion in neutrophils, recombinant netrin-1 rescue, myocardial I/R, patient samples\",\n      \"pmids\": [\"33891683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether netrin-1 binds ADORA2B directly or acts through a co-receptor not determined\", \"Relative contribution of netrin-1 versus adenosine to ADORA2B activation in vivo unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Genetic epistasis showed that myocyte ENT1 removes extracellular adenosine that otherwise activates myeloid ADORA2B, defining a complete intercellular signaling axis (myocyte ENT1 → adenosine pool → myeloid ADORA2B) controlling cardiac ischemic injury.\",\n      \"evidence\": \"Myocyte-specific ENT1 KO crossed with myeloid-specific Adora2b KO, cardiac adenosine measurements, I/R model\",\n      \"pmids\": [\"37288658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ENT2 has a compensatory role in myocytes not tested\", \"Quantitative threshold of extracellular adenosine needed for ADORA2B activation unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CD73-derived adenosine signals through ADORA2B to mediate immunosuppression in pancreatic cancer, positioning the CD73-ADORA2B axis as a targetable immune checkpoint in the tumor microenvironment.\",\n      \"evidence\": \"Genetically engineered and syngeneic PDAC mouse models with CD73 inhibitors, HPLC adenosine measurement, transcriptomics\",\n      \"pmids\": [\"36720042\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct genetic ADORA2B deletion in tumor or immune compartment not performed\", \"Which immune cell type mediates ADORA2B-dependent immunosuppression in PDAC not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstration that ADORA2B regulates red blood cell glycolytic flux and antioxidant defenses—and that caffeine impairs this signaling—extended ADORA2B's metabolic regulatory role to erythrocyte biology and transfusion medicine.\",\n      \"evidence\": \"Adora2b−/− mice storage/transfusion studies, recombinant G6PD inhibition assay, metabolomics in 13,091 human donors\",\n      \"pmids\": [\"40905089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ADORA2B acts via cAMP in mature enucleated RBCs not fully confirmed\", \"Direct protein interaction between ADORA2B signaling and G6PD not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the APIP–ADORA2B interaction, the molecular switch that converts ADORA2B from tissue-protective to pro-fibrotic in chronic settings, and whether netrin-1 directly binds ADORA2B or requires a co-receptor.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of ADORA2B or ADORA2B–APIP complex\", \"Mechanism of cell-type and context-dependent signaling polarity not defined\", \"Netrin-1 binding mode to ADORA2B unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 3, 6, 9, 15, 25]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 12, 14, 21, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 15, 7, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 7, 15, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 3, 8, 12, 17, 20]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 8, 14, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"APIP\",\n      \"PER2\",\n      \"NTN1\",\n      \"NT5E\",\n      \"SLC29A1\",\n      \"SLC29A2\",\n      \"HIF1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway term_ids. Let me check — I used \"GO:0162582\" which doesn't exist. The correct Reactome ID is \"R-HSA-162582\" for Signal Transduction. Let me correct:\n\n```json\n{\n  \"mechanistic_narrative\": \"ADORA2B is a low-affinity G protein-coupled adenosine receptor that functions as a master tissue-protective signal transducer during hypoxia, ischemia, and inflammation across multiple organ systems. Upon activation by extracellular adenosine—whose availability is regulated by ENT transporters and CD73—ADORA2B signals through cAMP/PKA and MAPK/CREB pathways to stabilize the circadian protein PER2 (which supports HIF-1α-dependent glycolytic metabolism in cardiomyocytes and hippocampal neurons), suppress neutrophil and macrophage TNF-α and IL-6 release, enhance regulatory T cell differentiation, activate SERCA2α-dependent calcium homeostasis, and regulate red blood cell glycolytic flux and antioxidant defenses [PMID:22504483, PMID:22531331, PMID:22389701, PMID:26136425, PMID:41751389, PMID:40905089]. ADORA2B expression is transcriptionally induced by HIF-1α during hypoxia and its protein stability is maintained through physical interaction with APIP, which prevents lysosomal degradation; the D296G variant that disrupts APIP binding abolishes cardioprotective activity [PMID:28701304, PMID:31263105]. Cell-type-specific functions are prominent: myeloid ADORA2B constrains neutrophil-dependent inflammation in cardiac and renal ischemia-reperfusion injury but drives alternatively activated macrophage-dependent pulmonary fibrosis and hypertension through IL-6 and hyaluronan production, while on pulmonary artery smooth muscle cells it induces vascular remodeling mediators including HAS2 and TGM2 [PMID:23028059, PMID:25318478, PMID:29910735, PMID:27320922].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing the genomic identity of human ADORA2B—chromosomal location (17p12) and gene structure with a coding-region intron—provided the foundational map for all subsequent molecular studies.\",\n      \"evidence\": \"FISH mapping and genomic cloning with partial sequencing\",\n      \"pmids\": [\"7558011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full promoter characterization not performed\", \"No functional data from expression of cloned gene\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstration that ADORA2B stabilizes PER2 during myocardial ischemia, enabling a HIF-1α-dependent metabolic switch to oxygen-efficient glycolysis, revealed the first mechanistic link between adenosine signaling, circadian clock components, and ischemic cardioprotection.\",\n      \"evidence\": \"Adora2b−/− and Per2−/− mouse ischemic preconditioning models with metabolic profiling and glycolytic enzyme induction\",\n      \"pmids\": [\"22504483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical mechanism of PER2 stabilization by ADORA2B not defined\", \"Whether PER2 stabilization is cAMP-dependent or uses another second messenger\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Reciprocal bone marrow transplants and neutrophil reconstitution experiments established that ADORA2B on myeloid cells—specifically PMNs—is the critical cell-type locus for suppressing TNF-α-dependent tissue injury in both cardiac and renal ischemia-reperfusion.\",\n      \"evidence\": \"WT↔Adora2b−/− bone marrow chimeras, neutrophil depletion/reconstitution with Tnf-α−/− neutrophils, myocardial and renal I/R models\",\n      \"pmids\": [\"22531331\", \"23028059\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling cascade from ADORA2B to TNF-α suppression in PMNs not delineated\", \"Whether other myeloid subtypes beyond PMNs contribute\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showing that ADORA2B is required for adenosine-driven regulatory T cell differentiation extended its immunomodulatory role beyond innate immunity to adaptive immune tolerance.\",\n      \"evidence\": \"Adora2b−/− T cells in endotoxin-induced pulmonary inflammation with flow cytometric Treg quantification\",\n      \"pmids\": [\"22389701\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ADORA2B acts cell-autonomously in T cells versus via antigen-presenting cells not fully resolved\", \"Downstream transcription factor linking ADORA2B to FOXP3 induction unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Tissue-specific conditional knockouts revealed that ADORA2B operates through distinct cell-type circuits—alveolar epithelium in acute lung injury, vascular endothelium in diabetic nephropathy—establishing that its protective function is context- and compartment-specific.\",\n      \"evidence\": \"Alveolar-epithelial and endothelial-specific Adora2b conditional KO mice in ventilator-induced ALI and streptozotocin diabetic nephropathy models\",\n      \"pmids\": [\"23603835\", \"24262796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether epithelial versus endothelial ADORA2B engage the same second messenger cascades\", \"Downstream targets in endothelial cells not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of ADORA2B as a downstream effector of Fra-1 that promotes filopodia formation and invasive activity in breast cancer introduced a pro-tumorigenic dimension to ADORA2B biology.\",\n      \"evidence\": \"RNAi, pharmacologic antagonism, and in vivo xenograft lung metastasis assays\",\n      \"pmids\": [\"23483055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ADORA2B drives invasion through cAMP or an alternative G-protein pathway not established\", \"Relevance to other cancer types unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Myeloid-specific ADORA2B deletion showed that on alternatively activated macrophages ADORA2B drives—rather than suppresses—pathological fibrosis and pulmonary hypertension via IL-6 and hyaluronan, revealing that ADORA2B's role switches from protective to pathogenic depending on chronicity and cell type.\",\n      \"evidence\": \"Adora2bf/f-LysMCre conditional KO mice in bleomycin lung fibrosis model with IL-6, CD206, arginase-1 readouts\",\n      \"pmids\": [\"25318478\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal that switches ADORA2B from anti-inflammatory to pro-fibrotic not identified\", \"Whether receptor desensitization differs between acute and chronic contexts\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Using three independent tissue-specific conditional knockouts in a single study definitively parsed ADORA2B's cardioprotective functions: endothelial and myocyte ADORA2B mediates preconditioning, while myeloid ADORA2B mediates post-ischemic protection.\",\n      \"evidence\": \"Lyz2-Cre, VE-cadherin-Cre, myosin-Cre × floxed Adora2b mice in myocardial I/R and ischemic preconditioning\",\n      \"pmids\": [\"26136425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distinct downstream effectors in each cell type not characterized\", \"Whether preconditioning and reperfusion signals converge on PER2 unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Establishing that HIF-1α transcriptionally induces ADORA2B on macrophages created a feedforward HIF-1α→ADORA2B→IL-6 circuit, explaining how hypoxia amplifies macrophage-driven fibrosis.\",\n      \"evidence\": \"HIF-1α inhibition in bleomycin model plus macrophage differentiation assays and human IPF samples\",\n      \"pmids\": [\"28701304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether HIF-1α directly binds ADORA2B promoter HREs not shown by ChIP\", \"Single lab finding\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"PASMC-specific ADORA2B deletion protected from pulmonary hypertension and identified HAS2 and TGM2 as downstream effectors, extending ADORA2B's pathogenic fibrotic axis to smooth muscle cells beyond myeloid cells.\",\n      \"evidence\": \"Adora2bf/f-Taglncre conditional KO in SUGEN/hypoxia and bleomycin PH models with RVSP and vascular remodeling\",\n      \"pmids\": [\"29910735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cAMP or another pathway activates HAS2/TGM2 transcription not defined\", \"Interaction with myeloid ADORA2B pathway unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that APIP physically interacts with ADORA2B and prevents its lysosomal degradation—and that the D296G variant disrupts this interaction and abolishes cardioprotection—provided the first post-translational regulatory mechanism for ADORA2B protein stability.\",\n      \"evidence\": \"Co-IP, proximity ligation assay, APIP transgenic/heterozygous KO mice, D296G knock-in mice, hypoxia assays\",\n      \"pmids\": [\"31263105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of APIP–ADORA2B interaction not resolved\", \"Whether APIP modulates ADORA2B signaling kinetics beyond stability unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of neutrophil-derived netrin-1 as an endogenous ligand-like activator of myeloid ADORA2B during myocardial I/R revealed an autocrine/paracrine loop that amplifies ADORA2B-dependent cardioprotection.\",\n      \"evidence\": \"Conditional netrin-1 deletion in neutrophils, recombinant netrin-1 rescue, myocardial I/R, patient samples\",\n      \"pmids\": [\"33891683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether netrin-1 binds ADORA2B directly or requires a co-receptor not determined\", \"Relative contribution of netrin-1 versus adenosine to ADORA2B activation in vivo unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Genetic epistasis showed that myocyte ENT1 removes extracellular adenosine that otherwise activates myeloid ADORA2B, defining a complete intercellular signaling axis (myocyte ENT1 → adenosine pool → myeloid ADORA2B) controlling cardiac ischemic injury.\",\n      \"evidence\": \"Myocyte-specific ENT1 KO crossed with myeloid-specific Adora2b KO, cardiac adenosine measurements, I/R model\",\n      \"pmids\": [\"37288658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ENT2 has a compensatory role in myocytes not tested\", \"Quantitative threshold of extracellular adenosine needed for ADORA2B activation unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CD73-derived adenosine signals through ADORA2B to mediate immunosuppression in pancreatic cancer, positioning the CD73-ADORA2B axis as a targetable immune checkpoint in the tumor microenvironment.\",\n      \"evidence\": \"Genetically engineered and syngeneic PDAC mouse models with CD73 inhibitors, HPLC adenosine measurement, transcriptomics\",\n      \"pmids\": [\"36720042\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct genetic ADORA2B deletion in tumor or immune compartment not performed\", \"Which immune cell type mediates ADORA2B-dependent immunosuppression in PDAC not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstration that ADORA2B regulates red blood cell glycolytic flux and antioxidant defenses—and that caffeine impairs this signaling—extended ADORA2B's metabolic regulatory role to erythrocyte biology and transfusion medicine.\",\n      \"evidence\": \"Adora2b−/− mice storage/transfusion studies, recombinant G6PD inhibition assay, metabolomics in 13,091 human donors\",\n      \"pmids\": [\"40905089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ADORA2B acts via cAMP in mature enucleated RBCs not fully confirmed\", \"Direct protein interaction between ADORA2B signaling and G6PD not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the APIP–ADORA2B interaction, the molecular switch that converts ADORA2B from tissue-protective to pro-fibrotic in chronic settings, and whether netrin-1 directly binds ADORA2B or requires a co-receptor.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of ADORA2B or ADORA2B–APIP complex\", \"Mechanism of cell-type and context-dependent signaling polarity not defined\", \"Netrin-1 binding mode to ADORA2B unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 3, 6, 9, 15, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 7, 15, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 3, 8, 12, 17, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 8, 14, 20]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"APIP\",\n      \"PER2\",\n      \"NTN1\",\n      \"NT5E\",\n      \"SLC29A1\",\n      \"SLC29A2\",\n      \"HIF1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}